全文获取类型
收费全文 | 28397篇 |
免费 | 1444篇 |
国内免费 | 342篇 |
专业分类
耳鼻咽喉 | 12篇 |
儿科学 | 721篇 |
妇产科学 | 185篇 |
基础医学 | 3053篇 |
口腔科学 | 38篇 |
临床医学 | 3382篇 |
内科学 | 10503篇 |
皮肤病学 | 33篇 |
神经病学 | 786篇 |
特种医学 | 950篇 |
外科学 | 2849篇 |
综合类 | 3636篇 |
预防医学 | 996篇 |
眼科学 | 15篇 |
药学 | 2054篇 |
13篇 | |
中国医学 | 831篇 |
肿瘤学 | 126篇 |
出版年
2023年 | 360篇 |
2022年 | 607篇 |
2021年 | 822篇 |
2020年 | 801篇 |
2019年 | 927篇 |
2018年 | 979篇 |
2017年 | 712篇 |
2016年 | 692篇 |
2015年 | 825篇 |
2014年 | 1987篇 |
2013年 | 1756篇 |
2012年 | 1472篇 |
2011年 | 1865篇 |
2010年 | 1517篇 |
2009年 | 1525篇 |
2008年 | 1615篇 |
2007年 | 1357篇 |
2006年 | 1361篇 |
2005年 | 1211篇 |
2004年 | 925篇 |
2003年 | 784篇 |
2002年 | 597篇 |
2001年 | 573篇 |
2000年 | 529篇 |
1999年 | 389篇 |
1998年 | 294篇 |
1997年 | 304篇 |
1996年 | 243篇 |
1995年 | 264篇 |
1994年 | 215篇 |
1993年 | 179篇 |
1992年 | 199篇 |
1991年 | 158篇 |
1990年 | 117篇 |
1989年 | 127篇 |
1988年 | 135篇 |
1987年 | 108篇 |
1986年 | 87篇 |
1985年 | 123篇 |
1984年 | 132篇 |
1983年 | 106篇 |
1982年 | 117篇 |
1981年 | 118篇 |
1980年 | 138篇 |
1979年 | 108篇 |
1978年 | 100篇 |
1977年 | 94篇 |
1976年 | 86篇 |
1975年 | 98篇 |
1973年 | 86篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
目的 探讨主动呼吸循环技术(ACBT)联合肺康复运动训练对慢性阻塞性肺疾病(COPD)康复期患者心率变异性(HRV)和肺功能的影响。方法 分析2017年8月~2019年8月到我院就诊的COPD康复期患者的临床资料,从采用常规肺康复训练治疗的患者中随机选取36例为常规训练组,从采用ACBT干预的患者中随机选取36例为ACBT组,从采用常规肺康复训练联合ACBT治疗的患者中随机选取36例为常规训练+ACBT组。对比3组患者干预前、干预12周后HRV指标[24 h正常RR间期标准差(SDNN)、连续5 min正常RR间期差值的均方根值(rMSSD)、正常相邻RR间期的间隔50 ms以上的百分比(PNN50)、低频(LF)以及高频(HF)]、肺功能指标[第1 s用气呼吸容积(FEV1)、用力肺活量(FVC)、呼气峰值流速(PEF)]、康复情况[6分钟步行距离(6MWD)、Borg呼吸困难评分(BS)]及生活质量(CRQ评分)的差异。结果 干预12周后,3组患者的HRV指标、肺功能指标及CRQ评分较干预前显著提高,且常规训练+ACBT组的上述指标显著高于ACBT组和常规训练组(均P<0.05);3组患者干预12周后的6MWD评分较干预前显著提高(均P<0.05),BS评分较干预前明显降低(均P<0.05),规训练+ACBT组的6MWD评分显著高于ACBT组及常规训练组,BS评分显著低于ACBT组及常规训练组(均P<0.05)。结论 ACBT联合肺康复运动训练对COPD康复期患者进行干预,可有效改善患者心率变异性,提升患者肺功能,促进康复,提升生活质量,具有较好的应用价值。 相似文献
2.
目的观察医护一体化管理模式对沙库巴曲缬沙坦治疗老年心力衰竭患者用药依从性及并发症的影响。 方法纳入2020年1月至12月江苏省人民医院心血管内科收治的老年心力衰竭患者106例,入院后给予强心、利尿等常规治疗,并在常规治疗的基础上加用沙库巴曲缬沙坦治疗。将106例患者按入院后管理方式的不同分为2组,对照组55例采用常规管理,医护一体化组51例采用医护一体化模式管理,患者出院后随访6个月。观察2组患者出院后总有效率、满意度、依从性和并发症发生率的差异。 结果出院后6个月随访可见,与对照组相比,医护一体化组患者并发症发生率显著降低(P<0.05),而总有效率、用药依从性和满意度均显著提高(P<0.05)。 结论对沙库巴曲缬沙坦治疗的老年心力衰竭患者而言,采用医护一体化管理模式可有效提高患者出院后的用药依从性,在提高总体疗效的同时还降低了并发症发生率。 相似文献
3.
4.
《Journal of Cardiovascular Computed Tomography》2022,16(6):517-523
BackgroundSelection of the transcatheter heart valve size for a mitral valve-in-valve procedure is based on the type and manufacturer’s labelled size. However, accurate information of surgical heart valve (SHV) size may not be available in the patient’s medical record. The purpose of this study is to establish reference data for computed tomography (CT) dimensions of commonly used mitral SHV in order to determine the manufacturer’s labelled size from a cardiac CT data set.MethodsCT datasets of 105 patients with surgical mitral bioprosthesis and available manufacturer labeled datasets were included in the analysis. CT derived valve dimensions were assessed by two observers using multiplanar reformats aligned with the basal sewing ring. A circular region of interest was used in a standardized fashion to minimize influence of image acquisition and reconstruction parameters. Interobserver variability was assessed by Bland-Altman analysis.ResultsThe CT-derived dimensions were stratified by valve size and type, and SHV properties were demonstrated for 5 common valve types. Variability of measurements was small and inter-observer limits of agreement were narrow. Stratified by SHV type, no overlap was noted for CT-derived dimensions among different SHV sizes . A reference table of CT characteristics of surgical mitral bioprosthesis types was created.ConclusionThe study provides reference CT data for determining the manufacturers’ labeled SHV size across a range of commonly used mitral SHVs. The findings will be important to help identify types of surgical mitral bioprosthesis utilizing CT characteristics for patients without SHV size documentation. 相似文献
5.
《Annales de cardiologie et d'angeiologie》2022,71(1):41-52
Heart failure (HF) has high event rates, mortality, and is challenging to manage in clinical practice. Clinical management is complicated by complex therapeutic strategies in a population with a high prevalence of comorbidity and general frailty. In the last four years, an abundance of research has become available to support multidisciplinary management of heart failure from within the hospital through to discharge and primary care as well as supporting diagnosis and comorbidity management. Within the hospital setting, recent evidence supports sacubitril-valsartan combination in frail, deteriorating or de novo patients with LVEF ≤ 40%. Furthermore, new strategies such as SGLT2 inhibitors and vericiguat provide further benefit for patients with decompensating HF. Studies with tafamidis report major clinical benefits specifically for patients with ATTR cardiac amyloidosis, a remaining underdiagnosed and undertreated disease. New evidence for medical interventions supports his bundle pacing to reduce QRS width and improve haemodynamics as well as ICD defibrillation for non-ischemic cardiomyopathy. The Mitraclip reduces hospitalisations and mortality in patients with symptomatic, secondary mitral regurgitation and ablation reduces mortality and hospitalisations in patients with paroxysmal and persistent atrial fibrillation. In end-stage HF, the 2018 French Heart Allocation policy should improve access to heart transplants for stable, ambulatory patients and, mechanical circulatory support should be considered to avoid deteriorating on the waiting list. In the community, new evidence supports that improving discharge education, treatment and patient support improves outcomes. The authors believe that this review fills the gap between the guidelines and clinical practice and provides practical recommendations to improve HF management. 相似文献
6.
《The Annals of thoracic surgery》2023,115(1):88-95
BackgroundRecent guidelines for the treatment of moderate or severe ischemic mitral regurgitation (IMR) in patients undergoing coronary artery bypass grafting (CABG) have changed. This study assessed the real-world impact of changing guidelines on the management of IMR during CABG over time. We hypothesized that the utilization of mitral valve repair for IMR would decrease over time, whereas mitral valve replacement for severe IMR would increase.MethodsPatients undergoing CABG in a statewide collaborative database (2011-2020) were stratified by severity of IMR. Trends in mitral valve repair or replacement were evaluated. To account for differences of the patients, propensity score–matched analyses were used to compare patients with and without mitral intervention.ResultsA total of 11,676 patients met inclusion criteria, including 1355 (11.6%) with moderate IMR and 390 (3.3%) with severe IMR. The proportion of patients undergoing mitral intervention for moderate IMR decreased over time (2011, 17.7%; 2020, 7.5%; Ptrend = .001), whereas mitral replacement for severe IMR remained stable (2011, 11.1%; 2020, 13.3%; Ptrend = .14). Major morbidity was higher for patients with moderate IMR who underwent mitral intervention (29.1% vs 19.9%; P = .005). In a propensity analysis of 249 well-matched pairs, there was no difference in major morbidity (29.3% with mitral intervention vs 23.7% without; P = .16) or operative mortality (1.2% vs 2.4%; P = .5).ConclusionsConsistent with recent guideline updates, patients with moderate IMR were less likely to undergo mitral repair. However, the rate of replacement for severe IMR did not change. Mitral intervention during CABG did not increase operative mortality or morbidity. 相似文献
7.
《Nutrition, metabolism, and cardiovascular diseases : NMCD》2022,32(8):1963-1971
Background and aimsThe relation of serum cystatin C with new-onset cardiovascular disease (CVD) remains uncertain. We aimed to evaluate the prospective associations of serum cystatin C and its change with new-onset CVD in Chinese general population.Methods and resultsA total of 7064 participants free of CVD at baseline were enrolled from the China Health and Retirement Longitudinal Study. The change in serum cystatin C was calculated as cystatin C concentration at 2015 wave minus that at baseline (2011 wave). The primary outcome was new-onset CVD, defined as self-reported physician-diagnosed heart disease, stroke, or both during follow-up. The secondary outcomes were new-onset heart disease, and new-onset stroke. During a median follow-up duration of 7.0 years, a total of 1116 (15.8%) subjects developed new-onset CVD. Overall, after the adjustments for eGFR and other important covariates, there was a positive association between serum cystatin C and new-onset CVD (per SD mg/L increment; adjusted HR, 1.13; 95%CI: 1.08,1.18). When cystatin C was assessed as quintiles, the adjusted HRs for participants in the second, third, fourth and fifth quintiles were 1.15 (95%CI: 0.93, 1.41), 1.37 (95%CI: 1.11, 1.68), 1.47 (95%CI: 1.19, 1.81), and 2.03 (95%CI: 1.60, 2.56), respectively, compared with those in quintile 1 (P for trend<0.001). Furthermore, there was a positive association between the increase in cystatin C concentration and the subsequent new-onset CVD (per SD mg/L increment; adjusted HR, 1.14; 95%CI: 1.02,1.27).ConclusionBoth serum cystatin C and its increase were positively associated with new-onset CVD among Chinese general population. 相似文献
8.
目的分析慢性心力衰竭患者血清氨基末端B型脑钠肽前体(NT-proBNP)、超敏C反应蛋白(hypersensitive C-reactive protein, hs-CRP)和糖类抗原-125(carbohydrate antigen-125, CA-125)水平特征。方法选取2019年1月-2020年12月沈阳医学院附属第二医院心血管内科收治的82例慢性心力衰竭患者纳入观察组,选取同期进行健康体检的82例健康者纳入对照组。对比分析两组患者血清NT-pro BNP、hs-CRP和CA-125水平,以及观察组治疗前后和不同心功能分级患者血清NT-pro BNP、hs-CRP和CA125水平的差异,分析心功能分级与血清NT-pro BNP、hs-CRP和CA-125水平的关系。结果观察组治疗前血清NT-pro BNP、hs-CRP和CA-125水平高于对照组,差异均具有统计学意义(P<0.05)。观察组治疗后血清NT-pro BNP、hs-CRP和CA-125水平较治疗前降低,差异均具有统计学意义(P<0.05)。观察组心功能Ⅲ级和Ⅳ级患者的血清NT-pro BNP、hs-CRP和CA-125水平高于心功能Ⅰ级和Ⅱ级患者,差异均具有统计学意义(P<0.05)。Spearman相关性分析显示,NT-pro BNP、hs-CRP和CA-125水平与患者的心功能分级呈正相关。结论慢性心力衰竭患者血清NT-pro BNP、hs-CRP和CA-125表达水平高于健康人群,且这3项指标与患者心功能分级呈正相关,可作为慢性心力衰竭患者病情评估的潜在指标。 相似文献
9.
10.